Last update: March 26, 2020

J05AR14 (+ Darunavir)

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Inhibidor selectivo de la isoenzima CYP3A del citocromo P450.
Aunque es, estructuralmente, un análogo del ritonavir, carece de acción antirretroviral en sí mismo. Se utiliza, al igual que el ritonavir, como potenciador farmacocinético para aumentar la biodisponibilidad y la semivida de eliminación de antirretrovirales como el atazanavir, el darunavir y el elvitegravir.
Se ha empleado de modo experimental, asociado a Darunavir, en el tratamiento de la infección por coronavirus COVID-19 (SEFH 2020).
Administración oral una vez al día.

A fecha de última actualización no encontramos datos publicados sobre su excreción en leche materna.

Sus datos farmacocinéticos (muy amplio volumen de distribución, peso molecular moderadamente elevado y muy alto porcentaje de fijación a proteínas) hacen poco probable el paso a leche materna de cantidades significativas.

Los efectos secundarios posibles, en combinación con Darunavir, son raros y, en general, de gravedad leve-moderada: diarrea, nauseas, exantema... (Navarro 2016).


See below the information of these related products:

Alternatives

We do not have alternatives for J05AR14 (+ Darunavir).

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

J05AR14 (+ Darunavir) is Cobicistat in ATC Code/s.

Is written in other languages:

Group

J05AR14 (+ Darunavir) belongs to this group or family:

Tradenames

Main tradenames from several countries containing J05AR14 (+ Darunavir) in its composition:

  • Prezcobix™. Contains other elements than J05AR14 (+ Darunavir) in its composition
  • Rezolsta™. Contains other elements than J05AR14 (+ Darunavir) in its composition
  • Symtuza™. Contains other elements than J05AR14 (+ Darunavir) in its composition
  • Tybost™

Pharmacokinetics

Variable Value Unit
Molecular weight 776 daltons
Protein Binding 97 - 98 %
VD 1,4 - 2,1 l/Kg
pKa 14,2 -
Tmax 3,5 hours
T1/2 3 - 4 hours

References

  1. SEFH - Sociedad Española de Farmacia Hospitalaria. Procedimientos de farmacia hospitalaria para la gestión del tratamiento con antivirales en la enfermedad por el nuevo coronavirus sars-cov-2 (COVID-19). Recomendaciones de la Sociedad Española de Farmacia Hospitalaria. 2020 Full text (in our servers)
  2. AEMPS - Gilead. Cobicistat (Tybost). Ficha técnica. 2018 Full text (in our servers)
  3. Navarro J, Curran A. Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS. HIV AIDS (Auckl). 2016 Oct 31;8:175-182. eCollection 2016. Review. Abstract
  4. EMA - Jansen C. Darunavir-Cobicistat (Rezolsta). Ficha técnica. 2014 Full text (in our servers)

Total visits

145

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM